xylazine has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Angelucci, ME; Anselmo-Franci, JA; Canteras, NS; Da Cunha, C; Ferro, MM | 1 |
1 other study(ies) available for xylazine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
Neuroprotective effect of ketamine/xylazine on two rat models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Anesthetics, Combined; Animals; Biogenic Monoamines; Corpus Striatum; Disease Models, Animal; Immunohistochemistry; Ketamine; Male; Maze Learning; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Substantia Nigra; Thiopental; Tyrosine 3-Monooxygenase; Xylazine | 2007 |